Dietary Protein Restriction Reprograms Tumor-Associated Macrophages and Enhances Immunotherapy
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Purpose: Diet and healthy weight are established means of reducing cancer incidence and mortality. However, the impact of diet modifications on the tumor microenvironment and antitumor immunity is not well defined. Immunosuppressive tumor-associated macrophages (TAMs) are associated with poor clinical outcomes and are potentially modifiable through dietary interventions. We tested the hypothesis that dietary protein restriction modifies macrophage function toward antitumor phenotypes. Experimental Design: Macrophage functional status under different tissue culture conditions and in vivo was assessed by Western blot, immunofluorescence, qRT-PCR, and cytokine array analyses. Tumor growth in the context of protein or amino acid (AA) restriction and immunotherapy, namely, a survivin peptide–based vaccine or a PD-1 inhibitor, was examined in animal models of prostate (RP-B6Myc) and renal (RENCA) cell carcinoma. All tests were two-sided. Results: Protein or AA-restricted macrophages exhibited enhanced tumoricidal, proinflammatory phenotypes, and in two syngeneic tumor models, protein or AA-restricted diets elicited reduced TAM infiltration, tumor growth, and increased response to immunotherapies. Further, we identified a distinct molecular mechanism by which AA-restriction reprograms macrophage function via a ROS/mTOR-centric cascade. Conclusions: Dietary protein restriction alters TAM activity and enhances the tumoricidal capacity of this critical innate immune cell type, providing the rationale for clinical testing of this supportive tool in patients receiving cancer immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · cited 1×
“Immune-checkpoint inhibitors are changing the therapeutic paradigm for several solid tumor types, including renal cell carcinoma (50, 51).”
BackgroundInteractions Between the Microbiota and the Immune System
Hooper, L. V., Littman, D. R., & Macpherson, A. J. (2012) · Science · doi:10.1126/science.1223490 · Cited by 4,173
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 2×
“Dietary M/CR alters the gut microbiota, which may contribute to immune system alterations Gut microbiota is influenced by dietary protein (42) and has been linked to immune activation in response to cancer treatments (43).”
BackgroundTargeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription
Kobayashi, E. H., Suzuki, T., Funayama, R., Nagashima, T., Hayashi, M., Sekine, H., Tanaka, N., Moriguchi, T., Motohashi, H., Nakayama, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms11624 · Cited by 1,878 · cited 2×
“Immune-checkpoint inhibitors are changing the therapeutic paradigm for several solid tumor types, including renal cell carcinoma (50, 51).”
BackgroundThe TSC-mTOR Signaling Pathway Regulates the Innate Inflammatory Response
Weichhart, T., Costantino, G., Poglitsch, M., Rosner, M., Zeyda, M., Stuhlmeier, K. M., Kolbe, T., Stulnig, T. M., Hörl, W. H., Hengstschläger, M., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.08.012 · Cited by 801 · cited 1×
“In response to nutrients and growth factors, the mTOR pathway controls pro-/anti-inflammatory cytokine expression in monocyte-derived macrophages and myeloid dendritic cells (11, 12).”
BackgroundZhou, Q., Munger, M. E., Veenstra, R. G., Weigel, B. J., Hirashima, M., Munn, D. H., Murphy, W. J., Azuma, M., Anderson, A. C., Kuchroo, V. K., et al. (2011) · Blood · doi:10.1182/blood-2010-10-310425 · Cited by 675
Tan, H.-Y., Wang, N., Li, S., Hong, M., Wang, X., & Feng, Y. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/2795090 · Cited by 657 · cited 3×
“AA restriction modulates the molecular programming of macrophage polarization AA restriction and oxidative stress have been shown to upregulate the cystine glutamate transporter, which regulates intracellular reactive oxygen species (ROS) that distinguish M1/M2 macrophage polarization phenotypes, xCT expression (32, 3…”
BackgroundInfluentialOrillion, A., Hashimoto, A., Damayanti, N., Shen, L., Adelaiye-Ogala, R., Arisa, S., Chintala, S., Ordentlich, P., Kao, C., Elzey, B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0741 · Cited by 373
Self-citationElshorbagy, A. K., Valdivia-Garcia, M., Mattocks, D. A. L., Plummer, J. D., Smith, A. D., Drevon, C. A., Refsum, H., & Perrone, C. E. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m010215 · Cited by 177
Cited by
Vernieri, C., Fucà, G., Ligorio, F., Huber, V., Vingiani, A., Iannelli, F., Raimondi, A., Rinchai, D., Frigè, G., Belfiore, A., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0030 · Cited by 319
“Because our FMD regimen is characterized by a severe restriction of both carbohydrates and proteins, the observed immunomodulatory effects could result from a combination of (i) carbohydrate restriction–induced reduction of blood glucose and CCL2, G-CSF, and GM-CSF levels, with consequently impaired monocyte mobilizat…”
BackgroundDietary regulation in health and disease
Wu, Q., Gao, Z.-J., Yu, X., & Wang, P. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01104-w · Cited by 176
“Mouse ↑ response to immunotherapies, ↑ proinflammatory phenotypes, ↓ tumour growth Orillion et al.(420)”
BackgroundHill, C. M., Albarado, D. C., Coco, L. G., Spann, R. A., Khan, M. S., Qualls-Creekmore, E., Burk, D. H., Burke, S. J., Collier, J. J., Yu, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29499-8 · Cited by 117
The effects of age and systemic metabolism on anti-tumor T cell responses
Drijvers, J. M., Sharpe, A. H., & Haigis, M. C. (2020) · eLife · doi:10.7554/elife.62420 · Cited by 69
“Accordingly, a shift in macrophage polarization accompanied by increased intratumoral CD8 T cell numbers and GzmB expression occurs in mice fed a methioninerestricted diet (Orillion et al., 2018).”
BackgroundThe impact of the gut microbiome on tumor immunotherapy: from mechanism to application strategies
Guo, C., Kong, L., Xiao, L., Liu, K., Cui, H., Xin, Q., Gu, X., Jiang, C., & Wu, J. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01135-y · Cited by 48
Metadata
- Authors
- Orillion, A., Damayanti, N. P., Shen, L., Adelaiye-Ogala, R., Affronti, H., Elbanna, M., Chintala, S., Ciesielski, M., Fontana, L., Kao, C., Elzey, B. D., Ratliff, T. L., Nelson, D. E., Smiraglia, D., Abrams, S. I., & Pili, R.
- Venue
- Clinical Cancer Research
- Published
- 2018-12-13
- Volume
- 24
- Issue
- 24
- Pages
- 6383-6395
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2891628726
- Cited by
- 121
- References
- 10
- FWCI
- 2.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dietary Protein Restriction Reprograms Tumor-Associated Macrophages and Enhances Immunotherapy. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-0980
- The paper
- Orillion, A., Damayanti, N. P., Shen, L., Adelaiye-Ogala, R., Affronti, H., Elbanna, M., Chintala, S., Ciesielski, M., Fontana, L., Kao, C., Elzey, B. D., Ratliff, T. L., Nelson, D. E., Smiraglia, D., Abrams, S. I., & Pili, R. (2018). Dietary Protein Restriction Reprograms Tumor-Associated Macrophages and Enhances Immunotherapy. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-0980
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.